natgillin/translations-raw huggingface dataset:
• upper respiratory tract infections such as cold, runny nose, sinus infection 
• okužbe zgornjih dihal, na primer prehlad, izcedek iz nosu, okužba obnosnih votlin,
If you stop taking Otezla 
Če ste prenehali jemati zdravilo Otezla
In both studies, the primary endpoint was the proportion of patients who achieved PASI-75 at week 16. 
V obeh študijah je bil primarni končni opazovani dogodek delež bolnikov, ki so do 16. tedna dosegli PASI 75.
Apremilast is contraindicated during pregnancy (see section 4.3). 
Apremilast je med nosečnostjo kontraindiciran (glejte poglavje 4.3).
Film-coated tablet Treatment initiation pack 
filmsko obložena tableta pakiranje za začetek zdravljenja
Week 16 Week 32 
16. teden 32. teden
Further improvements in nail psoriasis were observed at week 32 in patients continuously treated with apremilast. 
Nadaljnje izboljšanje psoriaze nohtov so ugotovili v 32. tednu pri bolnikih, ki so se ves čas zdravili z apremilastom.
Apremilast is extensively metabolised by both CYP and non-CYP mediated pathways including oxidation, hydrolysis, and conjugation, suggesting inhibition of a single clearance pathway is not likely to cause a marked drug-drug interaction. 
Apremilast se obsežno presnavlja z encimi CYP in s CYP neodvisnimi presnovnimi potmi, vključno z oksidacijo, hidrolizo in konjugacijo, kar kaže na to, da inhibicija ene same presnovne poti verjetno ne bo povzročila znatne interakcije med zdravili.
The clinical benefit of apremilast was demonstrated across multiple subgroups defined by baseline demographics and baseline clinical disease characteristics (including psoriasis disease duration and patients with a history of psoriatic arthritis). 
Klinično koristnost apremilasta so prikazali v več podskupinah, opredeljenih z izhodiščnimi demografskimi parametri in izhodiščnimi značilnostmi klinične bolezni (vključno s trajanjem psoriaze in bolniki z anamnezo psoriatičnega artritisa).
What Otezla is and what it is used for What you need to know before you take Otezla How to take Otezla 
Kaj je zdravilo Otezla in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Otezla Kako jemati zdravilo Otezla Možni neželeni učinki
Change in SF-36 MCS h, mean± SD 
SD sprememba DLQIg, povprečje ± SD sprememba SF-36 MCS h, povprečje± SD
You or your caregiver should also immediately inform your doctor of any changes in behaviour or mood and of any suicidal thoughts you may have. 
Vi ali vaš skrbnik nemudoma obvestite zdravnika o morebitnih spremembah vedenja ali razpoloženja in o morebitnih samomorilnih mislih.
Improved physical function as assessed by the HAQ-DI and the SF36v2PF domain, and the FACIT-fatigue scores were maintained in the open-label extension studies for up to 5 years of treatment. 
Izboljšano telesno delovanje, ocenjeno s HAQ-DI in domeno SF36v2PF, in rezultati FACIT-utrujenost so trajali v odprtih podaljšanih študijah do 5 let zdravljenja.
For initial dose titration in this group, it is recommended that apremilast be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped (see section 5.2). 
Za začetno titriranje odmerka v tej skupini se priporoča, da se apremilast titrira samo zjutraj, kot je navedeno v preglednici 1, večerni odmerki pa naj se izpustijo (glejte poglavje 5.2).
Patients received apremilast in combination with one or more of the following: methotrexate (MTX, ≤ 25 mg/week, 54.5%), sulfasalazine (SSZ, ≤ 2 g/day, 9.0%), and leflunomide (LEF; ≤ 20 mg/day, 7.4%). 
Bolniki so prejemali apremilast v kombinaciji z enim ali več od naslednjih zdravil: metotreksat (MTX, ≤ 25 mg/teden, 54,5 %), sulfasalazin (SSZ, ≤ 2 g/dan, 9,0 %) in leflunomid (LEF; ≤ 20 mg/dan, 7,4 %).
If patients suffered from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt is identified, it is recommended to discontinue treatment with apremilast. 
Če bolniki občutijo nove psihiatrične simptome oziroma se obstoječi poslabšajo, ali če se ugotovi, da imajo samomorilne misli ali so poskusili storiti samomor, se priporoča prekinitev zdravljenja z apremilastom.
ACR 20/50/70 responses were maintained at week 24. 
Odzivi ACR 20/50/70 so bili nadalje prisotni v 24. tednu zdravljenja.
After 40 weeks of treatment with apremilast, there was a decrease in plasma protein levels of IL-17 and IL-23, and an increase in IL-10. 
Po 40 tednih zdravljenja z apremilastom sta se zmanjšali koncentraciji plazemskih beljakovin IL-17 in IL-23, koncentracija IL-10 pa se je zvečala.
• bleeding in the bowel or in the stomach 
• krvavitev v črevo ali želodec,
Treatment with Otezla should be initiated by specialists experienced in the diagnosis and treatment of psoriasis or psoriatic arthritis. 
Zdravljenje z zdravilom Otezla morajo uvesti specialisti, ki imajo izkušnje v diagnostiki in zdravljenju psoriaze ali psoriatičnega artritisa.
In addition, in Study ESTEEM 1, significant improvement in the Work Limitations Questionnaire (WLQ-25) Index was achieved in patients receiving apremilast compared to placebo. 
Poleg tega so v študiji ESTEEM 1 dosegli signifikantno izboljšanje indeksa v vprašalniku o delovnih omejitvah (WLQ-25) pri bolnikih, ki so prejemali apremilast, v primerjavi s placebom.
Otezla works by reducing the activity of an enzyme in the body called ‘phosphodiesterase 4', which is involved in the process of inflammation. 
Zdravilo Otezla deluje tako, da v telesu zmanjšuje aktivnost encima, ki se imenuje ‘fosfodiesteraza 4' in je vpleten v proces vnetja.
PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. 
PDE4 je fosfodiesteraza, specifična za ciklični adenozinmonofosfat (cAMP), in prevladujoča fosfodiesteraza v vnetnih celicah.
Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1). 
Zdravilo Otezla, samo ali v kombinaciji z imunomodulirajočimi protirevmatičnimi zdravili (DMARDs - Disease Modifying Antirheumatic Drugs), je indicirano za zdravljenje aktivnega psoriatičnega artritisa (PsA) pri odraslih bolnikih, ki so se nezadostno odzvali na predhodno zdravljenje z DMARD ali ga niso prenašali (glejte poglavje 5.1).
MARKETING AUTHORISATION NUMBER(S) EU/1/14/981/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/14/981/001
8 subjects with severe renal impairment to whom a single dose of 30 mg apremilast was administered, the AUC and Cmax of apremilast increased by approximately 89% and 42%, respectively. 
Pri 8 preskušancih s hudo okvaro ledvic, ki jim je bil dan enkraten odmerek 30 mg apremilasta, se je AUC apremilasta zvečala za približno 89 % in Cmax za približno 42 %.
The most commonly reported adverse reactions with apremilast are gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%). 
Neželeni učinki, o katerih pri apremilastu najpogosteje poročajo, so gastrointestinalne (GI) motnje, ki vključujejo drisko (15,7 %) in navzeo (13,9 %).
Patients previously treated with DMARDs or biologics who received apremilast achieved a greater ACR 20 response at week 16 than patients receiving placebo. 
Bolniki, predhodno zdravljeni z DMARDs ali biološkimi zdravili, ki so prejemali apremilast, so po 16 tednih dosegli večji odziv ACR 20 kot bolniki, ki so prejemali placebo.
In the PsA or PSOR clinical studies, the safety profile observed in patients with mild renal impairment was comparable to patients with normal renal function. 
V kliničnih študijah PsA ali PSOR je bil varnostni profil, ki so ga opazili pri bolnikih z blago okvaro ledvic, primerljiv tistemu pri bolnikih z normalnim delovanjem jeter.
Apremilast can be co-administered with methotrexate. 
Apremilast lahko dajemo sočasno z metotreksatom.
Patients with each subtype of PsA were enrolled in the 3 studies, including symmetric polyarthritis (62.0%), asymmetric oligoarthritis (26.9%), distal interphalangeal (DIP) joint arthritis (6.2%), arthritis mutilans (2.7%), and predominant spondylitis (2.1%). 
V te 3 študije vključeni bolniki so imeli vse podtipe PsA, vključno s simetričnim poliartritisom (62,0 %), asimetričnim oligoartritisom (26,9 %), artritisom distalnih interfalangealnih (DIP) sklepov (6,2 %), artritisom mutilansom (2,7 %) in predominantnim spondilitisom (2,1 %).
You should not become pregnant while taking this medicine and should use an effective method of contraception during treatment with Otezla. 
Medtem ko jemljete to zdravilo, ne smete zanositi, med zdravljenjem z zdravilom Otezla pa morate uporabljati zanesljivo kontracepcijsko metodo.
In addition, apremilast demonstrated a treatment benefit across multiple manifestations of psoriasis including pruritus, nail disease, scalp involvement and quality of life measures. 
Poleg tega je apremilast pokazal koristnost zdravljenja pri številnih manifestacijah psoriaze, vključno s pruritusom, psoriazo nohtov, psoriazo lasišča in merilih kakovosti življenja.
For patients who remained on apremilast in the open label extension of ESTEEM 1 and ESTEEM 2 studies, improvements were generally maintained in PASI score, affected BSA, itch, nail and quality of life measures for up to 5 years. 
Pri bolnikih, ki so v odprtem podaljšanju študij ESTEEM 1 in ESTEEM 2 ostali na apremilastu, so izboljšanja na splošno trajala v rezultatu PASI, prizadeti telesni površini, srbenju, nohtih in merilih kvalitete življenja do 5 let.
Otezla should be dose reduced to 30 mg once daily in patients with severe renal impairment (see sections 4.2 and 5.2). 
Pri bolnikih s hudo okvaro ledvic je treba odmerek zdravila Otezla zmanjšati na 30 mg enkrat na dan (glejte poglavji 4.2 in 5.2).
The frequencies of adverse drug reactions are those reported in the apremilast arms of the four Phase III studies in PsA (n = 1,945) or the two Phase III studies in PSOR (n=1184) (highest frequency from either data pool is represented in Table 2). 
Pogostnosti neželenih učinkov zdravila so tiste, o katerih so poročali v skupinah z apremilastom v štirih študijah faze III pri PsA (n = 1.945) ali v dveh študijah faze III pri psoriazi (n=1.184) (največje pogostnosti iz enih ali drugih združenih podatkov so prikazane v preglednici 2).
Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). 
Zdravilo Otezla je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki se niso odzvali, je pri njih kontraindicirano ali ne prenašajo drugih vrst sistemskega zdravljenja, vključno s ciklosporinom, metotreksatom ali psoralenom in ultravijolično svetlobo A (PUVA).
Apremilast can be co-administered with oral contraceptives. 
Apremilast lahko dajemo skupaj s peroralnimi kontracepcijskimi sredstvi.
Other medicines and Otezla 
Druga zdravila in zdravilo Otezla
Apremilast pharmacokinetics are linear, with a dose-proportional increase in systemic exposure in the dose range of 10 to 100 mg daily. 
Farmakokinetika apremilasta je linearna, v območju odmerkov od 10 do 100 mg na dan se sistemska izpostavljenost zvečuje sorazmerno odmerku.
These GI adverse reactions are mostly mild to moderate in severity, with 0.3% of diarrhoea and 0.3% of nausea reported as severe. 
Ti GI neželeni učinki so po izraženosti večinoma blagi do zmerni, o hudi driski poročajo v 0,3 % in o hudi navzei prav tako v 0,3 %.
10 mg (pink) 
10 mg (rožnata)
Co-administration of apremilast with multiple doses of rifampicin resulted in a decrease in apremilast area-under-the-concentration time curve (AUC) and maximum serum concentration (Cmax) by approximately 72% and 43%, respectively. 
Sočasno dajanje apremilasta z večkratnimi odmerki rifampicina je povzročilo zmanjšanje površine pod krivuljo koncentracija-čas (AUC) za približno 72 % in največje serumske koncentracije (Cmax) apremilasta za približno 43 %.
If it is close to the time for your next dose, just skip the missed dose. 
Če je že skoraj čas za naslednji odmerek, ne vzemite izpuščenega odmerka.
The mean baseline PASI score was 19.07 (median 16.80), and the proportion of patients with sPGA score of 3 (moderate) and 4 (severe) at baseline was 70.0% and 29.8%, respectively with a mean baseline BSA involvement of 25.19% (median 21.0%). 
Srednji rezultat PASI v izhodišču je bil 19,07 (mediana 16,80), delež bolnikov z rezultatom sPGA 3 (zmerna) in 4 (huda) v izhodišču je bil 70,0 % oziroma 29,8 %, s povprečno BSA v izhodišču 25,19 % (mediana 21,0 %).
• The film-coating contains poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron oxide red (E172). 
• Filmska obloga vsebuje polivinilalkohol, titanov dioksid (E171), makrogol (3350), smukec, rdeči železov oksid (E172).
Response to apremilast was rapid, with significantly greater improvements in the signs and symptoms of psoriasis, including PASI, skin discomfort/pain and pruritus, compared to placebo by week 2. 
Odziv na apremilast je bil hiter, s signifikantno večjim izboljšanjem znakov in simptomov psoriaze po 2 tednih, vključno z odzivom PASI, neugodjem/bolečino v koži in pruritusom, v primerjavi s placebom.
If patients develop severe diarrhoea, nausea, or vomiting, discontinuation of treatment with apremilast may be necessary. 
Če se pri bolniku pojavi huda driska, navzea ali bruhanje, bo morda potrebna prekinitev zdravljenja z apremilastom.
• difficulty sleeping (insomnia) 
• motnje spanja (nespečnost),
In clinical studies, apremilast has been administered concomitantly with topical therapy (including corticosteroids, coal tar shampoo and salicylic acid scalp preparations) and UVB phototherapy. 
V kliničnih študijah so dajali apremilast sočasno s topikalno terapijo (vključno s kortikosteroidi, šamponom s premogovim katranom in pripravki za lasišče s salicilno kislino) in s fototerapijo z UVB.
Instances of suicidal ideation and behaviour, including suicide, have been observed in patients with or without history of depression (see section 4.8). 
Pri bolnikih z depresijo v anamnezi ali brez nje so opazili primere samomorilnih misli in vedenja, vključno s samomorom (glejte poglavje 4.8).
In clinical trials in patients with psoriasis, apremilast decreased lesional skin epidermal thickness, inflammatory cell infiltration, and expression of pro-inflammatory genes, including those for inducible nitric oxide synthase (iNOS), IL-12/IL-23p40, IL-17A, IL-22 and IL-8. 
V kliničnih preskušanjih pri bolnikih s psoriazo je apremilast zmanjšal debelino povrhnjice kožnih lezij, infiltracijo vnetnih celic in ekspresijo genov, ki pospešujejo vnetje, vključno s tistimi za inducibilno sintazo dušikovega oksida (iNOS), IL-12/IL-23p40, IL-17A, IL-22 in IL-8.
There were no apremilast-related effects on duration of pregnancy, number of pregnant mice at the end of the gestation period, number of mice that delivered a litter, or any developmental effects in the pups beyond postnatal day 7. 
Z apremilastom povezanih učinkov na trajanje brejosti, število brejih miši ob koncu obdobja brejosti, število miši, ki so skotile zarod, ali kakšnih učinkov na razvoj mladičev od 7. dne po skotitvi naprej ni bilo.
The results support that no dose adjustment is needed in patients with mild and moderate renal impairment. 
Rezultati so v prid trditvi, da pri bolnikih z blago in zmerno okvaro ledvic prilagajanje odmerka ni potrebno.
Otezla 10 mg, 20 mg, 30 mg film-coated tablets (initiation pack) PVC/ aluminium foil blisters containing 27 film-coated tablets (4 x10 mg, 4x 20 mg, 19 x 30 mg). 
Otezla 10 mg, 20 mg, 30 mg filmsko obložene tablete (pakiranje za začetek zdravljenja) Pretisni omoti iz PVC/aluminijeve folije, ki vsebujejo po 27 filmsko obloženih tablet (4 x 10 mg, 4 x 20 mg, 19 x 30 mg).
By reducing the activity of this enzyme, Otezla can help to control the inflammation associated with psoriatic arthritis and psoriasis, and thereby reduce the signs and symptoms of these conditions. 
Zdravilo Otezla lahko z zmanjšanjem aktivnosti tega encima pomaga obvladovati vnetje, ki je povezano s psoriatičnim artritisom in psoriazo, in tako zmanjšuje znake in simptome teh bolezni.
Migraine* Tension headache* Headache* 
Bolezni živčevja pogosti migrena* tenzijski glavobol* glavobol*
Name and address of the manufacturer responsible for batch release Celgene Distribution B.V. 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij Celgene Distribution B.V.
• The three-month standard pack contains 168 x 30 mg film-coated tablets. 
• Trimesečno standardno pakiranje vsebuje 168 x 30 mg filmsko obloženih tablet.
Increased peri- and postnatal pup deaths and reduced pup body weights during the first week of lactation were observed at ≥ 80 mg/kg/day (≥ 4.0-fold clinical exposure). 
Pogostnejše peri- in postnatalne smrti mladičev in zmanjšano telesno maso mladičev v prvem tednu laktacije so opazili pri odmerku ≥ 80 mg/kg/dan (≥ 4,0-kratna klinična izpostavljenost).
If you take more Otezla than you should, talk to a doctor or go to a hospital straight away. 
Če ste vzeli večji odmerek zdravila Otezla, kot bi smeli Če ste vzeli več zdravila Otezla, kot bi smeli, se posvetujte z zdravnikom ali pojdite takoj v bolnišnico.
• Do not use this medicine after the expiry date which is stated on the blister or on the wallet or on the carton after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu ali na zgibanki ali na škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Patients who did not achieve the designated PASI response by week 32, or who were initially randomised to placebo, remained on apremilast until week 52. 
Bolniki, ki do 32. tedna niso dosegli navedenega odziva PASI ali ki so bili v začetku randomizirani na placebo, so do 52. tedna ostali na apremilastu.
No such effects were observed when exposure in animals was at 1.3-fold the clinical exposure (see section 5.3). 
Kadar je bila izpostavljenost živali 1,3-krat večja od klinične izpostavljenosti, takih učinkov niso opazili (glejte poglavje 5.3).
The adverse reactions observed in patients treated with apremilast are listed below by system organ class (SOC) and frequency for all adverse reactions. 
Neželeni učinki, ki so jih opazili pri bolnikih, zdravljenih z apremilastom, so navedeni v nadaljevanju po organskih sistemih in pogostnosti za vse neželene učinke.
Patients with pre-existing enthesopathy (63%) or pre-existing dactylitis (42%) were enrolled. 
Vključili so tudi bolnike z entezopatijo (63 %) ali daktilitisom (42 %).
The major secondary endpoint was the proportion of patients who achieved a sPGA score of clear (0) or almost clear (1) at week 16. 
Najpomembnejši sekundarni končni opazovani dogodek je bil delež bolnikov, ki so v 16. tednu dosegli rezultat sPGA brez vidnih bolezenskih sprememb (0) ali skoraj brez vidnih bolezenskih sprememb (1).
Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. 
Apremilast, peroralni nizkomolekularni inhibitor fosfodiesteraze 4 (PDE4), deluje intracelularno z moduliranjem mreže mediatorjev, ki pospešujejo in zavirajo vnetje.
PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-α, IL-23, IL-17 and other inflammatory cytokines. 
Inhibicija PDE4 zviša koncentracijo intracelularnega cAMP, ki nato zmanjša vnetni odziv z moduliranjem ekspresije TNF-α, IL-23, IL-17 in drugih vnetnih citokinov.
In clinical studies in patients with psoriatic arthritis, apremilast significantly modulated, but did not fully inhibit, plasma protein levels of IL-1α, IL-6, IL-8, MCP-1, MIP-1β, MMP-3, and TNF-α. 
V kliničnih študijah pri bolnikih s psoriatičnim artritisom je apremilast signifikantno moduliral plazemske koncentracije beljakovin IL-1α, IL-6, IL-8, MCP-1, MIP-1β, MMP-3 in TNF-α, ni jih pa popolnoma inhibiral.
There was no clinically meaningful interaction between ketoconazole and apremilast. 
Med ketokonazolom in apremilastom ni bilo klinično pomembnih interakcij.
Increased numbers of early resorptions and reduced numbers of ossified tarsals were observed at 20, 40, and 80 mg/kg/day. 
Zvečano število zgodnjih resorpcij in zmanjšano število osificiranih tarzalnih kosti so opazili pri 20, 40 in 80 mg/kg/dan.
Otezla contains the active substance ‘apremilast'. 
Zdravilo Otezla vsebuje učinkovino ‘apremilast'.
In animal studies in mice, no adverse effects on fertility were observed in males at exposure levels 3-fold clinical exposure and in females at exposure levels 1-fold clinical exposure. 
V študijah na živalih niso ugotovili neželenih učinkov na plodnost pri mišjih samcih pri izpostavljenosti, ki je bila trikratnik klinične izpostavljenosti in pri mišjih samicah pri izpostavljenosti, ki je znašala 1-kratnik klinične izpostavljenosti.
Patients in these studies had a diagnosis of PsA for at least 6 months. 
Bolniki so imeli potrjeno diagnozo PsA vsaj 6 mesecev pred vključitvijo v študije.
Otezla contains lactose (a type of sugar). 
Zdravilo Otezla vsebuje laktozo (vrsta sladkorja).
NAME OF THE MARKETING AUTHORISATION HOLDER Celgene 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Celgene
In general, PASI responses were achieved by week 16 and were maintained through week 32. 
Na splošno so bolniki dosegli odzive PASI po 16 tednih, trajali pa so še po 32 tednih.
Based on the study design, patients whose tender and swollen joint counts had not improved by at least 20% were considered non-responders at week 16. 
Na podlagi zasnove študij so v 16. tednu bolnike, pri katerih se število občutljivih in oteklih sklepov ni zmanjšalo vsaj za 20 %, opredelili kot neodzivne na zdravljenje.
Patients with hepatic impairment No dose adjustment is necessary for patients with hepatic impairment (see section 5.2). 
Bolniki z okvaro jeter Pri bolnikih z okvaro jeter prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
Apremilast exposure is decreased when administered concomitantly with strong inducers of CYP3A4 (e.g. rifampicin) and may result in reduced clinical response. 
Izpostavljenost apremilastu se zmanjša, kadar ga dajemo sočasno z močnimi spodbujevalci CYP3A4 (npr. rifampicinom), kar lahko zmanjša klinični odziv.
Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
V razvrstitvah organskih sistemov in pogostnosti so neželeni učinki navedeni po padajoči resnosti.
Hence, clinically relevant drug-drug interactions are unlikely when apremilast is co-administered with drugs that are substrates or inhibitors of these transporters. 
Klinično pomembne interakcije med apremilastom in zdravili, ki so substrati ali zaviralci teh prenašalcev, niso verjetne.
Following oral administration of radiolabelled apremilast, about 58% and 39% of the radioactivity is recovered in urine and faeces, respectively, with about 3% and 7% of the radioactive dose recovered as apremilast in urine and faeces, respectively. 
Po peroralnem dajanju radioaktivno označenega apremilasta iz urina oziroma blata prestrežejo okrog 58 % oziroma 39 % radioaktivnosti, pri čemer je okrog 3 % oziroma 7 % prestreženega radioaktivnega odmerka v obliki apremilasta.
If your doctor considers you to be underweight, and you observe an unintentional loss of body weight while being treated with Otezla, you should talk to your doctor. 
Če zdravnik meni, da ste presuhi, in med zdravljenjem z zdravilom Otezla opazite nenamerno zmanjševanje telesne mase, se posvetujte z zdravnikom.
Driving and using machines Otezla has no effect on the ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Otezla ne vpliva na sposobnost upravljanja vozil in strojev.